Next-Generation Gynecological Cancer Diagnostics Market

1
Next-Generation Gynecological Cancer
Diagnostics Market - A Global Market and
Regional Analysis
res www.freepik.
com/premium-vector/dna-strand-molecular-structure-
genetic-engineering-l
Table of Content
T E K R A M S C I T S O N G A I D R E
C N A C L A
https//
aboratory-research_4927901.htm
C I G O L O C E N Y G N O I T A R E
N GE - T X E N L A B O 1 G L All rights
reserved at BIS Research Inc.
Focus on Technology, Product Type, End User, and
Country Analysis Analysis and Forecast
2020-2031 February 2022
2
BIS Research is a leading market intelligence and
technology research company. BIS Research
publishes in- depth market intelligence reports
focusing on the market estimations, technology
analysis, emerging high- growth applications,
deeply segmented granular country-level market
data and other important market parameters
useful in the strategic decision making for
senior management. BIS Research provides
multi-client reports, company profiles,
databases, and custom research services.
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
Copyright 2022 BIS Research Inc. All Rights
Reserved. This document contains highly
confidential information and is the sole property
of BIS Research. Disclosing, copying,
circulating, quoting or otherwise reproducing any
or all contents of this document is strictly
prohibited. Access to this information is
provided exclusively for the benefit of the
people or organization concerned. It may not be
accessed by or offered whether for sale or
otherwise to any third party.
2
3

• Table of Content
• 1. Definition.....................................
  ............................................. 27
• 1.1 Inclusion and Exclusion Criteria
  ..................................................
  ..................27
• 1.1.1 Inclusions..................................
  ..................................................
  .................27
• 1.1.2 Exclusions .................................
  ..................................................
  ................27
• 2. Research Scope ................................
  ....................................... 28
• 2.1 Key Questions Answered in the Report
  ..................................................
  ......29
• 3. Research Methodology ..........................
  ................................... 30
• 3.1 Global Next-Generation Gynecological Cancer
  Diagnostics Market Research Methodology
  ..................................................
  .................................30
• 3.2 Data Sources..................................
  ..................................................
  ................31
• 3.2.1 Primary Data Sources .......................
  ..................................................
  ........31
• 3.2.2 Secondary Data Sources .....................
  ..................................................
  .....32
• 3.3 Market Estimation Model.......................
  ..................................................
  ........32
• 3.4 Criteria for Company Profiling................
  ..................................................
  ......34
• 4. Market.........................................
  ............................................. 35
• 4.1 Introduction..................................
  ..................................................
  ..................36
• 4.2 Molecular Profiling and Techniques
  ..................................................
  ............37
• Role of Molecular Diagnostics in Gynecological
  Cancers ...........................39
• Diagnostic Technologies and Regulatory Landmarks
  Timeline in Gynecological Cancers
  ..................................................
  .................................40

GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
4

• 6.2 COVID-19 Impact Global Next-Generation
  Gynecological Cancer Diagnostics
  Market............................................
  ..............................................53
• 6.3 Pre- and Post-COVID-19 Impact Assessment
  ...............................................54
• 7. Market Dynamics................................
  ...................................... 55
• 7.1 Overview......................................
  ..................................................
  ...................55
• 7.2 Impact Analysis ..............................
  ..................................................
  ...............56
• 7.3 Market Drivers................................
  ..................................................
  ................56
• Subsequent Decline in Next-Generation Sequencing
  (NGS) Cost ..........56
• Increased Recommendations from Government
  Organizations and Scientific Societies...........
  ..................................................
  .........................57
• Increased Awareness and Shift Toward Personalized
  Medicine.............57 7.4 Market
  Restraints........................................
  ..................................................
  ...59
• Limited Food and Drug Administration (FDA)
  Approved Next- Generation Sequencing (NGS)
  tests.............................................
  .............59
• Complexities Involved with Overall
  Next-Generation Sequencing (NGS) Process and
  Result Interpretation ............................
  ......................59
• Reimbursement Challenges Across the Countries
  ..................................61 7.5 Market
  Opportunities.....................................
  ..................................................
  61
• Increased Market Investments and Government
  Funded Projects .........61
• Next-Generation Sequencing (NGS) Acceptance by
  Emerging Nations ................................
  ..................................................
  .......................62
• 8. Industry Insights..............................
  ......................................... 63
• 8.1 Overview......................................
  ..................................................
  ...................63
• 8.2 Legal Requirements and Framework in the
  U.S............................................63
  8.2.1 FDA Regulation.............................
  ..................................................
  .............63
• 8.2.2 CMS Regulation ...........................
  ..................................................
  ..............64
• 8.3 Legal Requirements and Framework in
  Europe............................................
  65

GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
4
5

• 8.6 Funding Scenario .............................
  ..................................................
  .............70
• 9. Market Segmentation ...........................
  .................................... 71
• 9.1 Global Next-Generation Gynecological Cancer
  Diagnostics Market (by Technology), Million,
  2020-2031 ........................................
  ...........................72
• 9.1.1 Overview ...................................
  ..................................................
  .................72
• 9.1.1.1 Polymerase Chain Reaction (PCR)
  ..................................................
  ................ 73
• 9.1.1.1.1 by Value ...............................
  ..................................................
  .................................. 73
• 9.1.1.1.2 by Volume ..............................
  ..................................................
  ................................ 74
• 9.1.1.2 Next-Generation Sequencing (NGS)
  ..................................................
  .............. 75
• 9.1.1.2.1 by Value ...............................
  ..................................................
  .................................. 76
• 9.1.1.2.2 by Volume ..............................
  ..................................................
  ................................ 76
• 9.1.1.2.3 Broad Panels............................
  ..................................................
  .............................. 77
• 9.1.1.2.3.1 by Value .............................
  ..................................................
  ............................. 77

GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
5
6

• 11.1 Overview.....................................
  ..................................................
  ....................88
• 11.2 Ovarian Cancer ..............................
  ..................................................
  ................89
• 11.3 Cervical Cancer..............................
  ..................................................
  ................90
• 11.4 Uterine Cancer ..............................
  ..................................................
  .................91
• Global Next-Generation Gynecological Cancer
  Diagnostics Market (by End User), Million,
  2020-2031 ................................ 92
• 12.1 Overview.....................................
  ..................................................
  ....................92
• 12.2 Academic and Research Institutes
  ..................................................
  ..............93
• 12.3 Hospitals and Ambulatory Centers
  ..................................................
  ..............94
• 12.4 Diagnostic Laboratories......................
  ..................................................
  ..........95
• 12.5 Other End Users .............................
  ..................................................
  ...............96
• Global Next-Generation Gynecological Cancer
  Diagnostics Market (by Region), Million,
  2020-2031.................................... 97
• 13.1 Overview.....................................
  ..................................................
  ....................97
• 13.2 North America ...............................
  ..................................................
  ...............100
• 13.2.1 U.S. ......................................
  ..................................................
  .....................103
• 13.2.2 Canada ....................................
  ..................................................
  .................104
• 13.3 Europe ......................................
  ..................................................
  ....................106
• 13.3.1 Germany....................................
  ..................................................
  ...............109
• 13.3.2 U.K. ......................................
  ..................................................
  .....................110
• 13.3.3 France.....................................
  ..................................................
  ..................111

GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
6
7

• 13.4.5 South Korea ...............................
  ..................................................
  ..............124
• 13.4.6 Rest-of-Asia-Pacific.......................
  ..................................................
  ..........125
• 13.5 Latin America ...............................
  ..................................................
  ................126
• 13.5.1 Brazil.....................................
  ..................................................
  ....................129
• 13.5.2 Mexico ....................................
  ..................................................
  ..................130
• 13.5.3 Rest-of-Latin America .....................
  ..................................................
  ........131
• 13.6 Rest-of-the-World (RoW) .....................
  ..................................................
  ........132
• 14. Competitive Landscape and Company
  Profiles........................ 133
• 14.1 Competitive Landscape .......................
  ..................................................
  .......134
• 14.2 Regulatory and Legal Activities
  ..................................................
  .................134
• 14.3 Synergistic Activities ......................
  ..................................................
  ............135
• 14.4 Mergers and Acquisitions ....................
  ..................................................
  .......136
• 14.5 Product Launches ............................
  ..................................................
  ...........137
• 14.6 Business Expansions..........................
  ..................................................
  ........138
• 14.7 Market Share Analysis, by Service Providers,
  2020 ...................................139
• 14.8 Market Share Analysis, by Product
  Manufacturers, 2020 ..........................141
  14.9 Growth Share Analysis, by Company,
  2019-2020 .......................................1
  42
• Growth Share Analysis, by Service Providers,
  2019-2020.....................142
• Growth Share Analysis, by Product Manufacturers,
  2019-2020 ............143 15. Company Profiles
  ..................................................
  ................. 145 15.1 Overview..............
  ..................................................
  .........................................145
  15.2 Agilent Technologies, Inc.
  ..................................................
  ..........................146 15.2.1 Company
  Overview .........................................
  ..........................................146
• 15.2.2 Role of Agilent Technologies, Inc. in the
  Global Next-Generation Gynecological Cancer
  Diagnostics Market ...............................
  ..............146

GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
8
15.2.8 SWOT Analysis .............................
..................................................
...........151 15.3 ARUP Laboratories
..................................................
......................................152 15.3.1
Company Overview .................................
..................................................
152 15.3.2 Role of ARUP Laboratories in the Global
Next-generation gynecological Cancer
Diagnostics Market................................
..............152 15.3.3 Key Customers of the
Company ..........................................
....................152 15.3.4 Key Competitors of
the Company.......................................
.....................153 15.3.5 SWOT Analysis
..................................................
........................................154 15.4 B
GI Genomics ......................................
..................................................
........155 15.4.1 Company Overview
..................................................
.................................155 15.4.2 Role
of BGI Genomics in the Global Next-Generation
Gynecological Cancer Diagnostics Market
..................................................
....................155 15.4.3 Key Customers of
the Company ......................................
........................155 15.4.4 Key
Competitors of the Company........................
....................................156 15.4.5
Business Strategies ..............................
..................................................
..156 15.4.6 SWOT Analysis .......................
..................................................
.................157 15.5 CENTOGENE N.V.
..................................................
........................................158 15.5.1
Company Overview ................................
..................................................
.158 15.5.2 Role of CENTOGENE N.V. in the Global N
ext-Generation Gynecological Cancer Diagnostics
Market ...........................................
..158 15.5.3 Key Customers of the Company
..................................................
............158 15.5.4 Key Competitors of the
Company...........................................
.................159 15.5.5 Financials............
..................................................
.....................................160 15.5.6
Key Insights About Financial Health of the
Company ...........................162 15.5.7
SWOT Analysis ....................................
..................................................
....163 15.6 F. Hoffmann-La Roche Ltd
..................................................
..........................164 15.6.1 Company
Overview .........................................
..........................................164 15.6
.2 Role of F. Hoffmann-La Roche Ltd in the Global
Next-Generation Gynecological Cancer Diagnostics
Market ...........................................
..164 15.6.3 Key Customers of the Company
..................................................
............164 15.6.4 Key Competitors of the
Company...........................................
.................165
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
9
15.6.5 Financials.................................
..................................................
................166 15.6.6 Key Insights About
Financial Health of the Company
...........................168 15.6.7 Business
Strategies .......................................
...........................................168
15.6.8 SWOT Analysis .............................
..................................................
...........169 15.7 Fulgent Genetics, Inc.
..................................................
.................................170 15.7.1
Company Overview .................................
..................................................
170 15.7.2 Key Customers of the Company
..................................................
............170 15.7.3 Key Competitors of the
Company...........................................
.................171 15.7.4 Financials...........
..................................................
......................................172 15.7.5
Key Insights About Financial Health of the
Company ...........................173 15.7.6
Business Strategies ..............................
..................................................
..173 15.7.7 SWOT Analysis .......................
..................................................
.................174 15.8 Illumina, Inc.
..................................................
.................................................1
75 15.8.1 Company Overview .......................
..................................................
..........175 15.8.2 Role of Illumina, Inc. in
the Global Next-Generation Gynecological Cancer
Diagnostics Market ...............................
.......................................175 15.8.3
Key Customers of the Company .....................
.........................................175 15.8.
4 Key Competitors of the Company..................
..........................................176 15.8
.5 Financials.....................................
..................................................
............177 15.8.6 Key Insights About
Financial Health of the Company
...........................179 15.8.7 SWOT
Analysis .........................................
.................................................1
80 15.9 Invitae Corporation.......................
..................................................
...............181 15.9.1 Company Overview
..................................................
.................................181 15.9.2
Role of Invitae Corporation in the Global Next-Gen
eration Gynecological Cancer Diagnostics Market
.............................................181 1
5.9.3 Key Customers of the Company
..................................................
............181 15.9.4 Key Competitors of the
Company...........................................
.................182 15.9.5 Financials............
..................................................
.....................................183 15.9.6
Key Insights About Financial Health of the
Company ...........................185 15.9.7
Business Strategies ..............................
..................................................
..185
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
10
15.9.8 SWOT Analysis .............................
..................................................
...........186 15.10 Konica Minolta, Inc.
..................................................
.....................................187 15.10.1 C
ompany Overview...................................
..........................................187 15.1
0.2 Role of Konica Minolta, Inc. in the Global
Next-Generation Gynecological Cancer Diagnostics
Market ...........................................
..187 15.10.3 Key Customers of the
Company...........................................
.............187 15.10.4 Key Competitors of the
Company ..........................................
...........188 15.10.5 Financials
..................................................
..........................................189 15.1
0.6 Key Insights About Financial Health of the
Company .....................191
15.10.7 Business Strategies.......................
..................................................
...191 15.10.8 SWOT Analysis.....................
..................................................
.............192 15.11 Laboratory Corporation of
America Holdings..................................
...........193 15.11.1 Company
Overview..........................................
...................................193 15.11.2 Rol
e of Laboratory Corporation of America Holdings
in the Global Next-Generation Gynecological
Cancer Diagnostics Market ....193 15.11.3 Key
Customers of the Company..........................
..............................193 15.11.4 Key
Competitors of the Company .......................
..............................194 15.11.5 Financia
ls ...............................................
.............................................195 1
5.11.6 Business Strategies........................
..................................................
..196 15.11.7 SWOT Analysis.......................
..................................................
...........197 15.12 Myriad Genetics, Inc.
..................................................
...................................198 15.12.1 Com
pany Overview.....................................
........................................198 15.12.
2 Role of Myriad Genetics, Inc. in the Global
Next-Generation Gynecological Cancer Diagnostics
Market ...........................................
..198 15.12.3 Key Customers of the
Company...........................................
.............198 15.12.4 Key Competitors of the
Company ..........................................
...........199 15.12.5 Financials
..................................................
..........................................200 15.1
2.6 SWOT Analysis.................................
..................................................
.201 15.13 OPKO Health, Inc. ....................
..................................................
....................202 15.13.1 Company
Overview..........................................
...................................202
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
11
15.13.2 Role of OPKO Health, Inc. in the Global
Next-Generation Gynecological Cancer Diagnostics
Market ...........................................
..202 15.13.3 Key Customers of the
Company...........................................
.............202 15.13.4 Key Competitors of the
Company ..........................................
...........203 15.13.5 Financials
..................................................
..........................................204 15.1
3.6 Key Insights About Financial Health of the
Company .....................206 15.13.7 SWOT
Analysis..........................................
..........................................207
15.14 QIAGEN N.V..................................
..................................................
................208 15.14.1 Company
Overview..........................................
...................................208 15.14.2 Rol
e of QIAGEN N.V. in the Global Next-Generation
Gynecological Cancer Diagnostics Market
.............................................208 1
5.14.3 Key Customers of the Company...............
.........................................208 15.14
.4 Key Competitors of the Company
..................................................
...209 15.14.5 Financials ........................
..................................................
..................210 15.14.6 Key Insights About
Financial Health of the Company
.....................212 15.14.7 Business
Strategies........................................
....................................212 15.14.8 SW
OT Analysis.......................................
.............................................213 1
5.15 Quest Diagnostics Incorporated
..................................................
................214 15.15.1 Company
Overview..........................................
...................................214 15.15.2 Rol
e of Quest Diagnostics Incorporated in the Global
Next- Generation Gynecological Cancer
Diagnostics Market .........................214 15
.15.3 Key Customers of the Company................
........................................214 15.15.
4 Key Competitors of the Company
..................................................
...215 15.15.5 Financials ........................
..................................................
..................216 15.15.6 SWOT
Analysis..........................................
..........................................217 15.1
6 Thermo Fisher Scientific Inc....................
..................................................
...218 15.16.1 Company Overview...................
..................................................
........218 15.16.2 Role of Thermo Fisher
Scientific Inc. in the Global Next- Generation
Gynecological Cancer Diagnostics Market
.........................218 15.16.3 Key
Customers of the Company..........................
..............................218 15.16.4 Key
Competitors of the Company .......................
..............................219
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
12
15.16.5 Financials ...............................
..................................................
...........220 15.16.6 Key Insights About
Financial Health of the Company
.....................222 15.16.7 SWOT
Analysis..........................................
..........................................223
Emerging companies ...............................
..................................... 224 15.17
Overview..........................................
..................................................
.............224 15.18 NgeneBio
..................................................
..................................................
....224 15.18.1 Company Overview.................
..................................................
..........224 15.18.2 Role of NgeneBio in the
Global Next-Generation Gynecological Cancer
Diagnostics Market ...............................
.......................................224 15.19
oncgnostics GmbH..................................
..................................................
....225 15.19.1 Company Overview..................
..................................................
.........225 15.19.2 Role of oncgnostics GmbH in
the Global Next-Generation Gynecological Cancer
Diagnostics Market ...............................
..............225 15.20 Self-screen B.V.
..................................................
...........................................226 15.
20.1 Company Overview.............................
................................................22
6 15.20.2 Role of Self-screen B.V. in the Global N
ext-Generation Gynecological Cancer Diagnostics
Market ...........................................
..226 15.21 Strata Oncology, Inc.
..................................................
...................................227 15.21.1 Com
pany Overview.....................................
........................................227 15.21.
2 Role of Strata Oncology, Inc. in the Global
Next-Generation Gynecological Cancer Diagnostics
Market ...........................................
..227
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
13
List of Figures
Impact Analysis of Market Drivers and
Opportunities in Global Next-Generation
Gynecological Cancer Diagnostics Market
Figure 1
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Technology), 2020 and 2031
Figure 2
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Product Type), 2020 and
2031
Figure 3
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Indication), 2020 and 2031
Figure 4
Global Next-Generation Gynecological Cancer
Diagnostics Market (by End User), 2020 and 2031
Figure 5
Figure 6
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Region), 2020-2031
Figure 7
Global Next-Generation Gynecological Cancer
Diagnostics Market Segmentation
Figure 8
Figure Global Next-Generation Gynecological
Cancer Diagnostics Market Methodology
Figure 9
Figure Bottom-Up Approach (Segment-Wise Analysis)
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
Figure 10
Figure Top-Down Approach (Segment-Wise Analysis)
Figure 11
Cervical Cancer, Incidence Cases and New Cases
(2008-2018)
Figure 12
Ovarian Cancer, Incidence Cases and New Cases
(2008-2018)
Figure 13
Molecular Diagnostics Evolution Timeline
Figure 14
Types of Molecular Diagnostics Technologies
Figure 15
Diagnostic Technologies and Regulatory Landmark
Timeline
Figure 16
Type of Non-Invasive Next Generation Novel
Molecular Diagnostics
Figure 17
Evolution of Sequencing Technologies
Figure 18
Difference Between Polymerase Chain reaction
(PCR) Across Three Generation Sequencing
Figure 19
Global Next-Generation Gynecological Cancer
Diagnostics Market, Million, 2020-2031
Figure 20
Potential Biomarkers for Gynecological Cancer
Detection
Number of Food and Drug Administration (FDA)
Approved Companion Diagnostics (CDx), (19982020)
Figure 21
Number of Food and Drug Administration (FDA)
Approved Companion Diagnostics (CDx) Assays by
Analytical Platform/Technology
Figure 22
Laboratory Setting and Testing Methodologies
Being Adopted by the Respondents Laboratories
Figure 23
Figure 24
Types of Molecular Testing for Cancer Performed
13
14
Figure 25
Global Next-Generation Gynecological Cancer
Diagnostics Market COVID-19 Impact
Figure 26
Impact of COVID-19 on Global Next-Generation
Gynecological Cancer Diagnostics Market
Figure 27
Global Next-Generation Gynecological Cancer
Diagnostics, Market Dynamics
Impact Analysis of Market Drivers and
Opportunities on Global Next-Generation
Gynecological Cancer Diagnostics Market
Figure 28
Figure 29
Cost per Human Genome (20142021)
Figure 30
Approved Number of Personalized Medicine
(20162020)
Percentage of Food and Drug Administration (FDA)
Approved Personalized Medicines (2015 2020)
Figure 31
Next-Generation Sequencing (NGS) for Human
Papillomavirus (HPV) Detection and
Characterization Process Steps
Figure 32
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Technology), 2020 and 2031
Figure 33
Global Next-Generation Gynecological Cancer
Diagnostics Market (Polymerase Chain Reaction
(PCR)), Million, 2020-2031
Figure 34
Global Next-Generation Gynecological Cancer
Diagnostics Market (Polymerase Chain Reaction
(PCR)), Thousand Units, 2020-2031
Figure 35
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
Global Next-Generation Gynecological Cancer
Diagnostics Market (Next-Generation Sequencing
(NGS)), Million, 2020-2031
Figure 36
Global Next-Generation Gynecological Cancer
Diagnostics Market (Next-Generation Sequencing
(NGS)), Thousand Units, 2020-2031
Figure 37
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Next-Generation
Sequencing (NGS), Broad Panels), Million,
2020-2031
Figure 38
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Next-Generation
Sequencing (NGS), Broad Panels), Thousand Units,
2020-2031
Figure 39
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Next-Generation
Sequencing (NGS), Targeted Gene Panels),
Million, 2020-2031
Figure 40
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Next-Generation
Sequencing (NGS), Targeted Gene Panels), Thousand
Units, 2020-2031
Figure 41
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Next-Generation
Sequencing (NGS), Single Gene Panels), Million,
2020-2031
Figure 42
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Next-Generation
Sequencing (NGS), Single Gene Panels), Thousand
Units, 2020-2031
Figure 43
Global Next-Generation Gynecological Cancer
Diagnostics Market (Other Technologies), Million,
2020-2031
Figure 44
14
15
Global Next-Generation Gynecological Cancer
Diagnostics Market (Other Technologies),
Thousand Units, 2020-2031
Figure 45
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Product Type), 2020 and
2031
Figure 46
Global Next-Generation Gynecological Cancer
Diagnostics Market (Services), Million, 2020-
2031
Figure 47
Global Next-Generation Gynecological Cancer
Diagnostics Market (Products), Million, 2020-
2031
Figure 48
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Indication), 2020 and 2031
Figure 49
Global Next-Generation Gynecological Cancer
Diagnostics Market (Ovarian Cancer), Million,
2020-2031
Figure 50
Global Next-Generation Gynecological Cancer
Diagnostics Market (Cervical Cancer), Million,
2020-2031
Figure 51
Global Next-Generation Gynecological Cancer
Diagnostics Market (Uterine Cancer), Million,
2020-2031
Figure 52
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
Global Next-Generation Gynecological Cancer
Diagnostics Market (by End User), 2020 and 2031
Figure 53
Global Next-Generation Gynecological Cancer
Diagnostics Market (Academic and Research
Institutes), Million, 2020-2031
Figure 54
Global Next-Generation Gynecological Cancer
Diagnostics Market (Hospitals and Ambulatory
Centers), Million, 2020-2031
Figure 55
Global Next-Generation Gynecological Cancer
Diagnostics Market (Diagnostic Laboratories), Mil
lion, 2020-2031
Figure 56
Global Next-Generation Gynecological Cancer
Diagnostics Market (Other End Users), Million,
2020-2031
Figure 57
Figure 58
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Region)
Figure 59
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Region), 2020-2031
Global Next-Generation Gynecological Cancer
Diagnostics Market (by Region), Million,
2020-2031
Figure 60
North America Next-Generation Gynecological
Cancer Diagnostics Market, Million, 2020- 2031
Figure 61
Figure 62
North America, Market Dynamics
North America Next-Generation Gynecological
Cancer Diagnostics Market (by Country), 2020-2031
Figure 63
16
Figure 64 U.S. Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 65 Canada Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 66 Europe Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 67 Europe, Market Dynamics
Figure 68 Europe Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-2031
Figure 69 Germany Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 70 U.K. Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 71 France Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 72 Italy Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 73 Spain Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 74 Netherlands Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 75 Rest-of-Europe Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020- 2031
Figure 76 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 77 APAC, Market Dynamics
Figure 78 APAC Next-Generation Gynecological Market (by Country), 2020-2031
Figure 79 China Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 80 Japan Next-Generation Cancer Gynecological Cancer Diagnostics Market, Million, 2020- 2031
Figure 81 India Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 82 Australia Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 83 South Korea Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 84 RoAPAC Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 85 Latin America Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020- 2031
Figure 86 Latin America, Market Dynamics
Figure 87 Latin America Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020- 2031
Figure 88 Brazil Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 89 Mexico Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 90 Rest-of-Latin America Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
Figure 91 RoW Next-Generation Gynecological Cancer Diagnostics Market, Million, 2020-2031
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
17
Figure 92 Share of Key Developments and Strategies, January 2019January 2022
Figure 93 Share of Regulatory and Legal Activities (by Company), January 2019January 2022
Figure 94 Share of Synergistic Activities (by Company), January 2019January 2022
Figure 95 Share of Mergers and Acquisitions (by Company), January 2019January 2022
Figure 96 Share of Product Launches (by Company), January 2019January 2022
Figure 97 Share of Business Expansions (by Company), January 2019January 2022
Figure 98 Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market (by Service Providers), 2020
Figure 99 Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market (by Manufacturers), 2020
Figure 100 Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by Service Providers), 2020
Figure 101 Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by Product Manufacturers), 2020
Figure 102 Shares of Key Company Profiles
Figure 103 Agilent Technologies, Inc. Product Portfolio
Figure 104 Agilent Technologies, Inc. Overall Financials/Revenue, Million, 2019-2021
Figure 105 Agilent Technologies, Inc. Revenue (by Segment), Million, 2019-2021
Figure 106 Agilent Technologies, Inc. Revenue (by Region), Million, 2019-2021
Figure 107 Agilent Technologies, Inc. RD Expenditure, Million, 2019-2021
Figure 108 Agilent Technologies, Inc. SWOT Analysis
Figure 109 ARUP Laboratories Service Portfolio
Figure 110 ARUP Laboratories SWOT Analysis
Figure 111 BGI Genomics Product Portfolio
Figure 112 BGI Genomics SWOT Analysis
Figure 113 CENTOGENE N.V. Service Portfolio
Figure 114 CENTOGENE N.V. Overall Financials/Revenue, Million, 2018-2020
Figure 115 CENTOGENE N.V. Revenue (by Business Segment), Million, 2018-2020
Figure 116 CENTOGENE N.V. Revenue (by Region), Million, 2018-2020
Figure 117 CENTOGENE N.V. RD Expenditure, Million, 2018-2020
Figure 118 CENTOGENE N.V. SWOT Analysis
Figure 119 F. Hoffmann-La Roche Ltd Product Portfolio
Figure 120 F. Hoffmann-La Roche Ltd Overall Financials/Revenue, Billion, 2019-2021
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
17
18
Figure 121 F. Hoffmann-La Roche Ltd Revenue (by Segment), Billion, 2019-2021
Figure 122 F. Hoffmann-La Roche Ltd Revenue (by Region), Billion, 2019-2021
Figure 123 F. Hoffmann-La Roche Ltd RD Expenditure, Billion, 2019-2021
Figure 124 F. Hoffmann-La Roche Ltd SWOT Analysis
Figure 125 Fulgent Genetics, Inc. Service Portfolio
Figure 126 Fulgent Genetics, Inc. Overall Financials/Revenue, Million, 2018-2020
Figure 127 Fulgent Genetics, Inc. Revenue (by Region), Million, 2018-2020
Figure 128 Fulgent Genetics, Inc. RD Expenditure, Million, 2018-2020
Figure 129 Fulgent Genetics, Inc. SWOT Analysis
Figure 130 Illumina, Inc. Product Portfolio
Figure 131 Illumina, Inc. Overall Financials/Revenue, Million, 2018-2020
Figure 132 Illumina, Inc. Revenue (by Business Segment), Million, 20182020
Figure 133 Illumina, Inc. Revenue (by Region), Million, 20182020
Figure 134 Illumina, Inc. RD Expenditure, Million, 2018-2020
Figure 135 Illumina, Inc. SWOT Analysis
Figure 136 Invitae Corporation Service Portfolio
Figure 137 Invitae Corporation Overall Financials/Revenue, Million, 2018-2020
Figure 138 Invitae Corporation Revenue (by Business Segment), Million, 20182020
Figure 139 Invitae Corporation Revenue (by Region), Million, 2018-2020
Figure 140 Invitae Corporation RD Expenditure, Million, 2018-2020
Figure 141 Invitae Corporation SWOT Analysis
Figure 142 Konica Minolta, Inc. Service Portfolio
Figure 143 Konica Minolta, Inc. Overall Financials/Revenue, Million, 2018-2020
Figure 144 Konica Minolta, Inc. Revenue (by Business Segment), Million, 2019-2020
Figure 145 Konica Minolta, Inc. Revenue (by Healthcare Business), Million, 2019-2020
Figure 146 Konica Minolta, Inc. Revenue (by Region), Million, 2018-2020
Figure 147 Konica Minolta, Inc. RD Expenditure, Million, 2018-2020
Figure 148 Konica Minolta, Inc. SWOT Analysis
Figure 149 Laboratory Corporation of America Holdings Service Portfolio
Figure 150 Laboratory Corporation of America Holdings Overall Financials/Revenue, Million, 2018-2020
Figure 151 Laboratory Corporation of America Holdings Revenue (by Segment), Million, 2018-2020
Figure 152 Laboratory Corporation of America Holdings Revenue (by Region), Million, 2018-2020
Figure 153 Laboratory Corporation of America Holdings SWOT Analysis
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
19
Figure 154 Myriad Genetics, Inc. Service Portfolio
Figure 155 Myriad Genetics, Inc. Overall Financials/Revenue, 2018-2020
Figure 156 Myriad Genetics, Inc. Revenue (by Business Segment), 2018-2020
Figure 157 Myriad Genetics, Inc. SWOT Analysis
Figure 158 OPKO Health, Inc. Service Portfolio
Figure 159 OPKO Health, Inc. Overall Financials/Revenue, Million, 2018-2020
Figure 160 OPKO Health, Inc. Revenue (by Business Segment), Million, 20182020
Figure 161 OPKO Health, Inc. Revenue (by Region), Million, 2018-2020
Figure 162 OPKO Health, Inc. RD Expenditure, Million, 2018-2020
Figure 163 OPKO Health SWOT Analysis
Figure 164 QIAGEN N.V. Product Portfolio
Figure 165 QIAGEN N.V. Overall Financials/Revenue, 2019-2021
Figure 166 QIAGEN N.V. Revenue (by Segment), 2019-2021
Figure 167 QIAGEN N.V. Revenue (by Region), 2019-2021
Figure 168 QIAGEN N.V. RD Expenditure, 2019-2021
Figure 169 QIAGEN N.V. SWOT Analysis
Figure 170 Quest Diagnostics Incorporated Service Portfolio
Figure 171 Quest Diagnostics Incorporated Overall Financials/Revenue, Million, 2018-2020
Figure 172 Quest Diagnostics Incorporated Revenue (by Business Segment), Million, 2018-2020
Figure 173 Quest Diagnostics Incorporated SWOT Analysis
Figure 174 Thermo Fisher Scientific Inc. Product Portfolio
Figure 175 Thermo Fisher Scientific Inc. Overall Financials, Million, 2018-2020
Figure 176 Thermo Fisher Scientific Inc. Revenue (by Business Segment), Million, 20182020
Figure 177 Thermo Fisher Scientific Inc. Revenue (by Region), Million, 20182020
Figure 178 Thermo Fisher Scientific Inc. RD Expenditure, Million, 2018-2020
Figure 179 Thermo Fisher Scientific Inc. SWOT Analysis
Figure 180 NgeneBio Product Portfolio
Figure 181 oncgnostics GmbH Product Portfolio
Figure 182 Self-screen B.V. Product Portfolio
Figure 183 Strata Oncology, Inc. Product Portfolio
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
20
List of Tables
Table 1
Risks Associated with the Types of Genes Related
to Hereditary Ovarian and Uterine Cancer
Table 2
Advantages and Limitations of Short-Read
Sequencing and Long-Read Sequencing
National Comprehensive Cancer Network (NCCN)
Recommended Predictive Molecular Testing in
Gynecological Cancer
Table 3
Food and Drug Administration (FDA) Approved
Companion Diagnostics (CDx) for Gynecological
Cancers
Table 4
Table 5
Reimbursement Scenario Across Major Countries
Regulatory Framework and Reimbursement Options of
NGS-Based Diagnostics Across Major Countries
Table 6
Table 7
Next-Generation Sequencing Clinical Utility in
Gynecological Cancers
Table 8
Services Offered by Key Players
Table 9
Products Offered by Key Players
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
21
BIS Research Offerings
We are on a mission to harness the potential of
disruptive technologies to make businesses thrive
in todays digital age. We have a vision to be a
leading and a preferred knowledge partner for
corporates and institutions worldwide and assist
them with market intelligence in the area of
emerging technologies, advisories, and other
innovative solutions.
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
Know More
Know More
Know More
Know More
22
Disclaimer
BIS Research Inc. provides valuable market
intelligence to an exclusive group of customers
in response to orders. The report is licensed
for the customer's internal use only and is
subject to restrictions set henceforth. This
document and its contents are confidential and
may not be further distributed, published or
reproduced, in whole or in part, by any medium
or in any form for any purpose, without the
express written consent of BIS Research Inc.
Customer will not disclose the contents of the
report, whether directly in any media or
indirectly through incorporation in a database,
marketing list, report or otherwise, or use or
permit the use of Information to generate any
statistical or other information that is or will
be provided to third parties or voluntarily
produce Information in legal proceedings.
Market reports are based on expectations,
estimates and projections as of the date such
information is available. Any recommendation
contained in this report may not be suitable for
all investors or businesses. The market
conclusions drawn are necessarily based upon a
number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of
the date of such statements, are inherently
subject to market fluctuations and business,
economic and competitive uncertainties, and
contingencies
GLOBAL NEXT- GENERATION GYNECOLOGICAL CANCER
DIAGNOSTICS MARKET
For more details regarding permission, please
contact us Email sales_at_bisresearch.com Tel 1
510 404 8135
23
BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite
313 Fremont, CA 94538 -1686 E-mail
hello_at_bisresearch.com Call Us 1-510-404-8135
Global Delivery Center Tower B First Floor,
Tapasya Corporate Heights, Greater Noida
Expressway, Sector 126, Noida, U.P., 201303,
India Tel [phone]
www.bisresearch.com